about
DNA damage response and prostate cancer: defects, regulation and therapeutic implicationsBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsGermline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.BRCA1 and Oxidative StressPALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsVariants in the ATM-CHEK2-BRCA1 axis determine genetic predisposition and clinical presentation of papillary thyroid carcinoma.Mutations in BRCA2 and taxane resistance in prostate cancerTargeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT studyMolecular pathways and targets in prostate cancerPARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesisScreening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients.Familial clustering of breast and prostate cancer and risk of postmenopausal breast cancer in the Women's Health Initiative Study.TRRUST: a reference database of human transcriptional regulatory interactions.Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.Loss of heterozygosity for chromosomal regions 15q14-21.1, 17q21.31, and 13q12.3-13.1 and its relevance for prostate cancer.Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.An inherited NBN mutation is associated with poor prognosis prostate cancerA personalised approach to prostate cancer screening based on genotyping of risk founder allelesInherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.Absence of loss of heterozygosity of BRCA1 in a renal tumor from a BRCA1 germline mutation carrier.Germline genetic profiling in prostate cancer: latest developments and potential clinical applications.Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease.EN2: a novel prostate cancer biomarker.The genetic epidemiology of prostate cancer and its clinical implications.Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer.Quantifying family dissemination and identifying barriers to communication of risk information in Australian BRCA families.Mutational landscape of the essential autophagy gene BECN1 in human cancers.Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer.Genetic predisposition to prostate cancer.Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond.The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.The evaluation of tools used to predict the impact of missense variants is hindered by two types of circularity.The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.Prediction of individual genetic risk to prostate cancer using a polygenic score.Is prostate cancer a Lynch syndrome cancer?Update on Screening for Urological Malignancies.Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans.Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic.
P2860
Q26829155-AA7EBC00-46CA-48E2-B00E-AAA858B83944Q26852274-9800F390-D9E3-4C40-AB6B-86F99E98739CQ27852185-4D072472-7F3A-4BE2-ADCF-A8A6C2CDBE20Q28388921-EE98C8FA-CDFD-4BFF-A468-D7987DA72921Q28584533-8094572E-BBFB-46AF-AA95-9D3A56A5A306Q33618910-A04703A7-393A-4EE0-A35F-196BCB1A688BQ33760096-3818C433-76A3-4785-8FC2-AA63CF0D0F9DQ33870601-EECABEEC-F7A9-4B4F-A3FB-06DFEBB9A159Q33927384-3C23129F-2CF7-45E6-B31E-93813F66F17DQ34365632-94B8539D-FC2E-4093-894B-FC9EAEC1D6D1Q34434937-F86F3B44-96C8-41D9-AF29-26865A318BA3Q34486808-25E50151-3B93-4E79-A53F-F5B891F9878AQ35687887-172B1186-6654-4CFB-88F5-50802ED713C9Q35728153-B544280A-EFC5-44F2-A8B7-1FCF6805F97FQ35952814-C379F5F0-F703-47D2-96E5-4C2AFE347A76Q36118895-5BC1BC75-2EA6-4904-AEB2-5A92C687059FQ36356727-60B16651-0C65-4928-BB84-5CF3F07DCF4CQ36594121-6EBA1B58-937C-4BC3-A64A-66738947A763Q36959139-1CE5495B-D9FF-4CF3-8B55-463EC59A522CQ37179254-8C9CAA25-E608-4E6C-8FAA-0FDFA934C741Q37356519-4DE8F7C8-0EBA-4557-A8BF-2D33D75ACDAEQ37474516-EA72073F-4359-4E53-933E-CC9627E78CA2Q37650650-C8B56B29-016F-4A55-9FE4-C98894F4D94CQ38165246-8F1406EF-35B9-4A75-B2CB-52170B33AE75Q38168060-CF9E438B-9603-4EF8-A2D1-7424DF29D06CQ38622610-FCF05F9E-857E-43B1-B318-6F0B181F15D0Q38685321-90881B29-D75A-44E4-B383-B7077BA54028Q38794128-C4278899-634C-4BAA-A1FD-43B1361ACCF1Q38893354-5FAFBBAD-7781-486D-8146-6C0332F6E7D8Q39035687-42CCA3D9-BE6B-4E3A-B3B3-0E0B93BCFDD9Q39141778-A41D889C-13C9-4B5F-A899-63635C6765E6Q39190147-5F839D7F-45D7-413D-93BA-D2816EBA3713Q39951063-F25584E9-ADCD-470E-AEC0-CFC81A8E6B4EQ40625913-CE145B56-D8FA-4F84-AB97-CBB4407A559AQ41373360-19F0A5DD-9BFB-4948-9AC1-18B240B30217Q41584352-240BD23A-F3AA-43EA-97AA-76E83D800D0DQ41852329-7B5546E1-5E82-44ED-A5CC-965EEC6D9505Q42649779-3DCDCA83-49B1-4DAC-A581-34D25F39E5ADQ42731004-BAB47D27-63A6-4B1B-87C1-22D384903D60Q43047229-6890BB50-93FE-4933-AF35-EF4B980ED03B
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Germline BRCA1 mutations increase prostate cancer risk
@ast
Germline BRCA1 mutations increase prostate cancer risk
@en
type
label
Germline BRCA1 mutations increase prostate cancer risk
@ast
Germline BRCA1 mutations increase prostate cancer risk
@en
prefLabel
Germline BRCA1 mutations increase prostate cancer risk
@ast
Germline BRCA1 mutations increase prostate cancer risk
@en
P2093
P2860
P50
P356
P1476
Germline BRCA1 mutations increase prostate cancer risk
@en
P2093
K Govindasami
M Tymrakiewicz
R Wilkinson
UKGPCS Collaborators
P2860
P2888
P304
P356
10.1038/BJC.2012.146
P407
P50
P577
2012-05-01T00:00:00Z